Title of innovation: Substituted 1,2,3-triazoles as antitumor agents: As per WHO report cancer is the second leading cause of death globally, and there were 8.8 million deaths in 2015. A new concept called \"immunotherapy\" is being developed by medicinal chemists and oncologists for the treatment of cancer. But a drug development in this field is still under progress. Traditional cancer drugs kill cancer cells and also kill immune cells, which is called immunosuppression. Immunosuppression reduces the immunity of the human body and thereby increasing the risks of infections, malignancy, cardiovascular disease, and bone marrow suppression. Hence, there is an urgent necessity for the development of anticancer drugs with non-immunosuppressive effect. We have developed a new chemical entity (NCE) SPS-7, which is a triazole-containing molecule which exhibits anticancer activity against human prostate cancer, without having immunosuppression activity. This is a new concept. The NCE shows excellent antitumor activity in animal model. The clinical study on human is being planned.